HXBM Stock Overview
Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Helix BioMedix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.27 |
| 52 Week High | US$23.36 |
| 52 Week Low | US$23.00 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -50.80% |
| Change since IPO | -94.36% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| HXBM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.2% |
| 1Y | n/a | 0.7% | 24.9% |
Return vs Industry: Insufficient data to determine how HXBM performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how HXBM performed against the US Market.
Price Volatility
| HXBM volatility | |
|---|---|
| HXBM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HXBM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HXBM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | Robin Carmichael | www.helixbiomedix.com |
Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities.
Helix BioMedix, Inc. Fundamentals Summary
| HXBM fundamental statistics | |
|---|---|
| Market cap | US$5.23m |
| Earnings (TTM) | -US$2.58m |
| Revenue (TTM) | US$2.07m |
0.0x
P/S Ratio0.0x
P/E RatioIs HXBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HXBM income statement (TTM) | |
|---|---|
| Revenue | US$2.07m |
| Cost of Revenue | US$641.22k |
| Gross Profit | US$1.42m |
| Other Expenses | US$4.01m |
| Earnings | -US$2.58m |
Last Reported Earnings
Sep 30, 2012
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did HXBM perform over the long term?
See historical performance and comparison